After going ‘crazy’ over the science, Merck signs up a new partner in the hunt for an HIV cure
Authors | Max Gelman |
---|---|
Published | July 13, 2020 |
Topics | |
Keywords | |
Source | View at Endpoints News |
Less than a year after inking a $100 million licensing deal with German giant Bayer, Dewpoint Therapeutics has scored another big-time contract, this time with Merck. And this collaboration came together in a particularly unusual fashion.
Merck and Dewpoint have agreed on a partnership that will provide the pharma giant with access to the Boston-based biotech’s biomolecular condensate technology in order to develop treatments, and potentially a cure, for the HIV virus. Dewpoint, in turn, will receive up to $305 million in upfront and milestone payments as well as royalties for any approved product…
Join the conversation